Literature DB >> 2998714

Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine.

T Hoshino, T Nagashima, J Murovic, E M Levin, V A Levin, S M Rupp.   

Abstract

At the time of surgery, 18 patients with various brain tumors were given a 1-h i.v. infusion of bromodeoxyuridine (BrdUrd), 150-200 mg/m2. At an infusion rate of 200 mg/m2/h, serum BrdUrd levels of 8 microM were achieved. After the infusion, tumor tissue was obtained and divided into two portions. One portion was fixed in 70% ethanol, embedded in paraffin, and sectioned; the sections were deparaffinized, denatured with 2 N HCl, and reacted with monoclonal antibodies against BrdUrd (anti-BrdUrd MAb). BrdUrd-labeled nuclei were demonstrated satisfactorily by an indirect peroxidase method. The other portion was dissociated into single cells with a DNase enzyme cocktail and reacted with FITC-conjugated anti-BrdUrd MAb to determine the percentage of BrdUrd-labeled cells or with chromomycin A3 for DNA analysis. The single-cell suspensions were analyzed by flow cytometry. The fraction of S-phase cells in the tissue sections was similar to both the percentage of BrdUrd-labeled nuclei and the S-phase fraction determined by flow cytometric analysis. The results obtained with BrdUrd-labeled nuclei were similar to those obtained from previous autoradiographic studies of various brain tumors exposed to a pulse of 3H-thymidine. Since BrdUrd is not radioactive and is nontoxic at the dosage used, these techniques, together with the histopathological diagnosis, may help to predict the biological malignancy of individual tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998714     DOI: 10.1002/cyto.990060619

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  25 in total

1.  Correlation between nucleolar organizer region score and bromodeoxyuridine labeling index in C6 glioma cell line.

Authors:  A Hara; S Niikawa; H Hirayama; N Sakai; H Yamada; T Ohno; T Tanaka; H Mori
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  Nucleolar organizer region score and Ki-67 labelling index in high-grade gliomas and metastatic brain tumours.

Authors:  A Hara; H Hirayama; N Sakai; H Yamada; T Tanaka; H Mori
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

3.  Advances in cell kinetics.

Authors:  D A Rew; G D Wilson
Journal:  BMJ       Date:  1991-09-07

4.  [Cell cycle specific expression of the HER-2/NEU oncogene in breast cancer cell lines].

Authors:  E Ehrhart; J Fontaine; G Unteregger; N Blin
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

5.  Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67.

Authors:  M Deckert; G Reifenberger; W Wechsler
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 6.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

7.  Variability in the proliferative potential of human gliomas.

Authors:  T Hoshino; T Nagashima; K G Cho; R L Davis; J Donegan; M Slusarz; C B Wilson
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

Review 8.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Prolongation of G1 phase in cultured glioma cells by cis-dichlorodiammineplatinum (II) (CDDP): analysis using bromodeoxyuridine (BrdU)-Hoechst technique.

Authors:  T Morimura
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

10.  The applications of the BrdUrd-technique for the estimation of cycling S-phase cells in human renal cell carcinoma.

Authors:  E M Langer; J Hemmer; G Kleinhans; W Göhde
Journal:  Urol Res       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.